Homo sapiens
Ontology highlight
ABSTRACT:
PROVIDER: PRJNA345314 | ENA |
REPOSITORIES: ENA
Similar Datasets
Project description:The objective of these experiments is to identify novel direct and indirect targets of miR-150-5p in breast cancer cell lines. The goal is that these will give direction as to what targets or pathways may be contributing to the reduced growth observed in these cell lines upon restoration of miR-150-5p. A therapy directed towards one or more critical subtype-specific targets could be developed as a therapeutic for breast cancer patients. Using has-miR-150-5p mirVana miRNA mimic (Ambion, 4464066), miR-150-5p was restored to a triple negative breast cancer cell line, BT-549.
2017-01-01 | GSE87589 | GEO
Project description:We analysed aquired chemotherapeutic resistance of two different triple negative breast cancer cell lines BT-549 (Doxorubicin resistance) and MDA-MB-468 (5-Fluorouracil) by comparing the proteome of the parental cell line with the resistant cell line.
2018-02-23 | PXD008522 | Pride
Project description:The goal for this experiment was to analyze how knockdown of homeobox transcription factor Meox1 altered functional and mechanist biology of p53 and PTEN deficient triple negative breast cancer in vitro cell lines of claudin-low BT-549 and basal-like MDA-MB-468.
2020-05-26 | GSE133927 | GEO
Project description:Restoring miR-150-5p to breast cancer cell lines
| PRJNA345308 | ENA
Project description:The objective of these experiments is to identify novel direct and indirect targets of miR-150-5p in breast cancer cell lines. The goal is that these will give direction as to what targets or pathways may be contributing to the reduced growth observed in these cell lines upon restoration of miR-150-5p. A therapy directed towards one or more critical subtype-specific targets could be developed as a therapeutic for breast cancer patients. Using has-miR-150-5p mirVana miRNA mimic (Ambion, 4464066), miR-150-5p was restored to an estrogen receptor positive breast cancer cell line, ZR-75-1.
2017-01-01 | GSE87588 | GEO
Project description:Purpose: In this study, we performed RNA-seq analysis as a screening strategy to identify EV-miRNAs derived from serum of well clinically annotated breast cancer (BC) patients from South of Brazil. Methods: EVs from three groups of samples, healthy controls (CT), luminal A (LA), and triple negative (TNBC), were isolated from serum using a precipitation method and analyzed by RNA-seq (screening phase). Subsequently, four EV-miRNAs (miR-142-5p, miR-150-5p, miR-320a, and miR-4433b-5p) were selected to be quantified by RT-qPCR in individual samples (test phase). Results: A panel composed of miR-142-5p, miR-320a, and miR-4433b-5p discriminated BC patients from CT with an AUC of 0.8387 (93.33% sensitivity, 68.75% specificity). In addition, the combination of miR-142-5p and miR-320a, presented an AUC of 0.941 (100% sensitivity, 93.80% specificity) in distinguishing LA patients from CT. Interestingly, decrease expression of miR-142-5p and miR-150-5p were significantly associated with more advanced tumor grades (grade III), while the decrease expression of miR-142-5p and miR-320a with larger tumor size. Conclusion: These results provide insights into the potential application of EVs-miRNAs from serum as novel specific markers for early diagnosis of BC.
2020-03-16 | GSE141326 | GEO
Project description:Restoring miR-150-5p to an estrogen receptor positive breast cancer cell line [ZR-75-1]
| PRJNA345315 | ENA
Project description:two luminal cell lines were added, MCF7 and BT-474 two TNBC cell line were added, MB231 and BT-549
2014-10-03 | GSE62022 | GEO
Project description:Overexpression of miR-183-5p|+2, but not of the other two isomiRs |0 and |+1, was observed to reduce cell cycle and cell proliferation in different triple-negative breast cancer cell lines. Therefore, we hypothesized that the |+2 isoform has targets distinct from the other two isoforms. To test this hypothesis, we overexpressed separately the three different isoforms or negative controls (siAllstar or mimic-Cltr) and performed Mass Spectrometry to identify differentially regulated proteins. Interestingly, a gene set enrichment analysis of the changes in protein expression revealed significant downregulation of transcriptional targets of E2F specifically in cells transfected with the |+2 isoform prompting us to validate the predicted isomiR specific target E2F1. Subsequently, we could show that direct targeting of E2F1 by miR-183-5p|+2 is responsible for the impact of the isomiR on cell cycle and proliferation.
2022-05-26 | PXD026763 | Pride
Project description:Exosomes are a subset of extracellular vesicles shuttling proteins, RNA, DNA and lipids crucial for cell–to–cell communication. Recent findings highlighted that exosomes, by virtue of their cargo, may also contribute to breast tumor growth and dissemination of metastasis. Indeed, these vesicles are gaining great interest as non-invasive cancer biomarkers. However, little is known on exosome biological and physical properties from breast malignant lesions and even less by non–malignant lesions such as breast fibroadenoma. The latter, being a non-malignant lesion, is clinically managed by conservative approaches. However, the molecular features of fibroadenoma are still largely unknown. In this pilot study, we attempt to purify and explore the proteomic profiling of breast benign and tumor exosomes from breast fibroadenoma, HER2+ and triple negative patient tumors as well from continuous cell lines by combining experimental and semi-quantitative approaches (BT-549, MCF10-A and MDA-MB-231). Interestingly, proteome-wide analyses showed 49 common proteins across breast fibroadenoma, HER2+, triple-negative malignant lesions and model cell exosomes. This is the first feasibility study evaluating physicochemical composition and proteome of extracellular vesicles from breast benign, malignant primary cells and immortalized cells. Our preliminary results may hold promises for freshly isolated primary cells protein identification with possible implications in breast cancer precision medicine.
2022-05-31 | PXD027197 | Pride